摘要
目的探讨卡瑞利珠单抗、培美曲塞及顺铂化疗联用在晚期非小细胞肺癌(NSCLC)中的应用效果.方法选取2020年2月—2022年2月六安市中医院收治的85例晚期NSCLC患者为研究对象,按随机数字表法分为对照组(n=43)和观察组(n=42).对照组采用培美曲塞及顺铂化疗,观察组在对照组基础上加用卡瑞利珠单抗治疗,均3周为1个疗程,持续治疗3个疗程.比较两组临床疗效、血清肿瘤标志物水平、免疫功能、生活质量以及不良反应.结果观察组疾病控制率较对照组高,治疗后癌胚抗原、糖类抗原125、糖类抗原199、细胞角质素片段抗原21-1水平分别为(24.69±2.14)U/mL、(40.35±4.28)U/mL、(39.85±4.12)U/mL、(5.15±1.07)ng/mL,均低于对照组的(28.54±2.47)U/mL、(48.24±4.39)U/mL、(45.63±4.25)U/mL、(6.85±1.22)ng/mL,组间差异有统计学意义(P<0.05).观察组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)分别为(51.58±4.13)%、(33.14±3.22)%、(1.02±0.22),均高于对照组的(46.82±4.02)%、(29.86±2.81)%、(0.83±0.15),CD8^(+)为(32.36±3.41)%,低于对照组的(36.11±3.55)%,组间差异有统计学意义(P<0.05).观察组治疗后世界卫生组织生活质量测定量表简表中生理、心理、环境及社会领域评分分别为(84.35±7.12)分、(82.04±6.89)分、(88.96±7.25)分、(86.32±7.18)分,均高于对照组的(76.65±7.02)分、(74.34±6.52)分、(80.45±7.19)分、(78.63±6.95)分,组间差异有统计学意义(P<0.05).两组不良反应发生率相比,差异无统计学意义(P>0.05).结论卡瑞利珠单抗联合培美曲塞及顺铂化疗可提高晚期NSCLC的疾病控制效果,增强机体免疫功能,降低肿瘤标志物水平,且安全性良好.
Objective To investigate the application effect of Camrelizumab combined with Pemetrexed and Cisplatin chemotherapy in non-small cell lung cancer(NSCLC).Methods 85 patients with advanced NSCLC admitted to the Lu'an Hospital of Traditional Chinese Medicine from February 2020 to February 2022 were selected as the research objects,and divided into a control group(n=43)and an observation group(n=42)according to random number table method.The control group was treated with Pemetrexed and Cisplatin,and the observation group was treated with Camrelizumab on the basis of the control group.Both groups were treated for 3 weeks as a course of treatment and continued for 3 courses.The clinical efficacy,serum tumor marker levels,immune function,quality of life and adverse reactions were compared between the two groups.Results The disease control rate in the observation group was higher than that in the control group,after treatment,the levels of carcinoembryonic antigen,carbohydrate antigen 125,carbohydrate antigen 199,cytokeratin fragment antiogen 21-1 in the observation group were(24.69±2.14)U/mL,(40.35±4.28)U/mL,(39.85±4.12)U/mL,(5.15±1.07)ng/mL,respectively,which were lower than(28.54±2.47)U/mL,(48.24±4.39)U/mL,(45.63±4.25)U/mL,(6.85±1.22)ng/mL of the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the observation group were(51.58±4.13)%,(33.14±3.22)%,(1.02±0.22),respectively,which were higher than(46.82±4.02)%,(29.86±2.81)%,(0.83±0.15)in the control group,CD8^(+)in the observation group was(32.36±3.41)%,which was lower than(36.11±3.55)%in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the physiological,psychological,environmental and social scores of the World Health Organization quality of life brief questionnaire in the observation group were(84.35±7.12)points,(82.04±6.89)points,(88.96±7.25)points,(86.32±7.18)points,respectively,which were higher than(76.65±7.02)points,(74.34±6.52)points,(80.45±7.19)points and(78.63±6.95)points in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Camrelizumab combined with Pemetrexed and Cisplatin can improve the disease control effect of advanced NSCLC,enhance immune function of the body,and reduce the level of tumor markers,with good safety.
作者
谷雨
许斌
GU Yu;XU Bin(Graduate School,Anhui University of Traditional Chinese Medicine,Hefei Anhui,230022,China;Department of Tumor Radiotherapy,Lu'an Hospital of Traditional Chinese Medicine,Lu'an Anhui,237000,China)
出处
《反射疗法与康复医学》
2023年第2期113-116,共4页
Reflexology And Rehabilitation Medicine
作者简介
谷雨(1996-),女,安徽阜阳人,在读硕士研究生,研究方向:中西医结合肿瘤诊疗。
